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The HIV pandemic continues to rage with an estimated
33 million people living with HIV globally by December 2007
and with a staggering 2.5 million new infections in 2007
alone. Countries in the frontline of the disease continue
to struggle with the increasing human and social burden of
this disease which in turn has become a major threat to
country development and growth. On the upside, the world
has seen major advances in HIV medicine esp. in the use of
antiretroviral (ARV) agents in recent years. This has been
mainly due to the development of new therapeutic agents
including better formulations of the older products (eg. heat
stable lopinavir and enteric coated didanosine) as well as
new agents in the established ARV classes eg. new protease
inhibitors, which generally have some advantage over the
earlier compounds (atazanavir, darunavir, etc). While these
have all led to signiﬁcant improvements in patient outcome
either by way of improving adherence (by decreasing pill
burden, improving convenience, improved adverse event
proﬁles, etc) or improved potency towards drug resistant
viral populations ie. agents with different resistant mutation
proﬁles, the major cause for the heightened optimism in HIV
treatment is the rapid development and approval of new
ARV drug classes including the fusion inhibitors, integrase
inhibitors and most recently the CCR5 chemokine receptor
antagonist. All these agents have signiﬁcantly improved
patient outcomes in the developed world esp. with regards
to the improved capability to put together potent 2nd. and
3rd. line ARV regimens. Despite these major advancements,
new challenges do remain with regards to the need for
more clinical data esp. on how best to use these agents in
the real world setting, how they should be best combined,
monitoring of new potential adverse events, etc. The other
major challenge is the ever persistent issue of equitable
access. While ﬁrst line ARV agents are available in most
3rd. world countries (with varying levels of access), 2nd.
line options are generally poor in the developing and less
developed world. Intelligent sequencing of various ARV
regimens, so as to ensure potent and well tolerated 1st.
line regimens and at the same time having effective salvage
regimens in reserve, remains integral in the successful
management of HIV infection. Effective salvage regimens
would depend greatly on a sound understanding of HIV
viral mutation as well as the availability of tools (eg. viral
resistance assays) to assist in ARV selection.
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Cryptococcus neoformans is the most common cause of
fungal meningitis worldwide. Cryptococcal meningitis is a
common opportunistic infection and AIDS deﬁning illness
in patients with late-stage HIV infection. The mortality
of cryptococcosis meningitis in AIDS patients is still high.
Treatment of AIDS patients with cryptococcosis meningitis
should be timely, reasonable and effective. However,
authoritative guideline of this scope for reference is
still lacking in China. Shanghai Public Health Clinical
Center is the only AIDS designed hospital in Shanghai
and we had admitted more than 30 AIDS cases
with cryptococcosis meningitis. Combining the clinical
experience and literature, we summarized the principle
of the management of patients with AIDS and cryptococcal
meningitis.
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Background: Tuberculosis (TB) is still a major public health
problem around world, especially in China, AIDS epidemic
have make TB infection more complex than that before.
This study is to evaluate TB speciﬁc T-cell responses in
Chinese HIV infected patients without TB disease by using
the recombinant ESAT-6 and CFP-10 protein as stimulus.
Methods: In house IFN-g based ELISPOT assay was used
to detect ESAT-6 and CFP-10 speciﬁc T-cell responses
separately in HIV (+) patients without clinical manifestation
of TB diseases.
Results: ESAT-6 speciﬁc T-cell responses were detected in
60 of HIV(+) patients without active TB disease, the median
positive frequency was 19 CPU/106 PBMC (inter-quartile
range from 10 51 5 to 51), 14 of 60 patients (23.3%) show
relatively high frequencies (more than 50 CPU/106 PBMC) in
HIV(+) patients without clinical TB diseases. Similarly, CFP-
10 speciﬁc T-cell responses were detected in 73 of HIV(+)
patients without active TB disease, the median positive
frequency was 17 SFC/106 PBMC (inter-quartile range from
5 to 51), 18 of 73 patients (24.7%) show relatively high
frequencies (more than 50CPU/106 PBMC) in HIV(+) patients
without clinical TB diseases.
Conclusions: This was a pilot study for IFN-g based ELISPOT
assay by using recombinant ESAT-6 and CFP-10 protein as
stimulus to detect TB speciﬁc T-cell responses in Chinese HIV
(+) individuals without active TB disease, the high positive
frequency of T-cell responses were detected in more than
23% of this population, further longitudinal assessment is
needed to observe if those positive responses to ESAT-6 and
CFP-10 are related to latent TB infection in Chinese HIV (+)
population.
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Selection of patients for therapy: There is now good
evidence that the best predictive factor for the
development of cirrhosis and hepatocellular carcinoma is
serum HBVDNA concentration. The higher the HBVDNA
concentration, the higher the risk of HCC. Therefore the
viral load is a major factor in determining whether a
patient should be treated. Normal ALT does not exclude that
advanced ﬁbrosis or cirrhosis might be present. Therefore
normal ALT is not a reason to exclude patients from
treatment.
Therefore, patients who need treatment for hepatitis B are
those who have a viral load greater than 4 5 log copies/ml
and evidence of liver injury. This might be in the form of
persistently elevated ALT, or if the ALT is normal, includes a
liver biopsy. However, if the biopsy shows regressed ﬁbrosis
this should be taken as evidence of more advanced liver
disease.
